Close Menu
Home » Cepheid Outlines Assay Improvements, Xpert Cartridge Partnering Program at ECCMID

Cepheid Outlines Assay Improvements, Xpert Cartridge Partnering Program at ECCMID

Apr 15, 2019
|
Ben Butkus
Premium

AMSTERDAM (GenomeWeb) – A Cepheid executive today provided an update on upcoming improvements to various Xpert real-time PCR-based molecular assays and outlined a new partnering program that aims to validate and commercialize third-party assays on the company's Xpert microfluidic test cartridges.

In addition, an early user of a new Xpert-based Mycoplasma genitalium and antibiotic resistance test from SpeeDx, Cepheid's first cartridge partner, shared initial validation data on the assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Aiming for the Mutations

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Why in Decline?

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Time Off and a Connection

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

Genome Research Papers Examine Epigenetic Aging and Method to ID CNVs

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.

What's Popular?

In Business News

  1. BD Files Patent Infringement Suit Against NeuMoDx

  2. UK Request Pushes Illumina's Timeline for Completion of PacBio Acquisition to Q4

  3. Invitae to Acquire Singular Bio for $55M

  4. Adaptive Biotechnologies Expects Planned IPO to Fetch $15 to $17 a Share

  5. Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.